Siemens Healthineers AG announces that it has completed the acquisition of Waltham, Mass.-based Corindus Vascular Robotics, which develops, produces, and sells a robotic-assisted platform. Corindus is currently the only FDA-cleared and CE-marked robotic system for endovascular coronary and peripheral vascular interventions, according to Siemens officials.

This technology helps physicians to precisely control guide catheters, guide wires, or balloon or stent implants via integrated imaging. Thanks to the platform, the physician does not have to stand directly at the angiography table as is current practice, but can control the procedure with a separate controlling module; therefore, the physician is exposed to less radiation.

Siemens Healthineers AG CEO Bernd Montag believes this technology—and, more specifically, the acquisition of Corindus—will be a boon to operations. “With the completion of the acquisition, we are opening up a new field for our Advanced Therapies business, tapping into adjacent growth markets with great potential for the future. We are taking an important step forward in the upgrading phase of our 2025 strategy,” Montag says.

Mark J. Toland, former president and CEO of Corindus, also spoke out about the acquisition, commenting: “The combination of Siemens Healthineers’ strong medical technology portfolio with its digital platforms and solutions, together with Corindus’ precision robotics platform, has the potential to transform healthcare delivery so that, together, we can provide better care at lower cost.” Toland will continue to manage the business within Siemens Healthineers.